The global cancer biologics market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period. Cancer is the third most lethal disease in the world, after cardiovascular and infectious diseases. The treatment of cancer includes surgery, radiation, chemotherapy, vaccines, and drugs. The surgery is the first step of therapy which is used for the early stage of cancer. Cell and gene therapy seeks to modify or manipulate the gene or to alter the biological properties of living cells for therapeutic use. The management of cancer in the patients requires the use of different therapy such as hormonal therapy, immunotherapy, targeted therapy, and chemotherapy. The major drivers responsible for the growth of the market, are the surge in the geriatric population, early screening of different types of cancer, and rise in the number of R&D activities to develop cancer biologics have significantly contributed toward the growth of the market. For instance, in December 2020, Food and Drug Administration (FDA), has approved pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer, and those who require systematic therapy.  

Impact of COVID-19 Pandemic on Global Cancer biologics Market 

During the COVID-19 pandemic, lung cancer patients are severely affected, as they are at a higher risk of COVID-19. The lockdown has affected the supply chain and disrupted the supply of raw material and finished products, from the manufacturing site to the end-user. Delay in the supply chain, has weakened several immunotherapy cancer drugs and diagnosis machines. Shortage of essential raw material during the COVID-19 pandemic could mean slower growth of the cancer biologics market. COVID-19 pandemic has directly affected the supply of biologics drug and cancer diagnosis machines, not only it is just difficult to manage chemotherapy and other treatment outside the hospital premises, but the COVID-19 pandemic has also reduced the patient’s willingness, and capacity to access not just the treatments, but the clinical trials of new medicine.          

Segmental Outlook 

The global cancer biologics market is segmented based on type, and distribution channel. Based on type, the market is segmented into monoclonal antibodies, vaccines, and cell and gene therapy. Based on the distribution channel the market is sub-categorized into, hospitals, and clinics. Based on type, the vaccine is expected to be the fastest-growing segment of the global cancer biologics segment. Government initiatives, improving healthcare spending, and the high demand for effective vaccines in developing countries, are further boosting the growth of the vaccine segment. For instance, In June 2020 the U.S. Food and Drug Administration (FDA), has approved an expansion for Gardasil 9- human papillomavirus (HPV), a nine-valent vaccine, for the prevention, of oropharyngeal, head, and neck cancers which is caused by HPV types 16,18,31,33,45,52, and 58?

Global Cancer biologics Market Share by Type, 2022 (%)

The Monoclonal Antibodies Holds the Major Share in the Global Cancer biologics Market 

The monoclonal antibodies therapy is a fast emerging extraordinary tool, used for the treatment of chronic diseases, especially cancer. The benefits of the monoclonal antibodies result in higher preferences for these drugs, resulting in blockbuster sales of a few products such as Herceptin, Humira, Remicade, and Rituxan. Moreover, monoclonal antibodies are designed to function in different ways, particular monoclonal drug functions by more than one means, for instance, cancer cells in the body if coated in monoclonal antibodies easily detected and become the target for destruction; monoclonal antibodies block the connection between a cancer cell and proteins that promote the growth of the cell. Further, when monoclonal antibodies, connect with a small radioactive particle, it transports the radiation treatment directly to cancer cells and helps in minimizing the effect of radiation on a healthy cell of the body. Owing to its advent features, it helps in treating cancer patients more early than other forms of treatment, this boost the demand of monoclonal antibodies over the forecast period. 

Regional Outlooks

The global cancer biologics market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America accounted for the largest share of revenue in 2022 and is expected to maintain its presence over the forecast period, owing to the presence of a large cancer patient population, ease of availability of drugs, reimbursement policies in the healthcare system contributes to the major market share in the region.  ?

Global Cancer Biologics Market Growth, by Region 2022-2028

The North-America Region Holds the Major Share in the Global Cancer biologics Market 

North America dominated the market by accounting highest share in the cancer biologics market in 2022. The region is further projected to maintain its dominance during the forecast period. The US and Canada are the major economies driving the regional market growth. The rising cancer patients in these economies are the major factor for the market growth. In addition, the government support in form of funding for R&D of pharmaceuticals drugs and investments by the pharmaceutical industry on R&D activities is further supporting the market growth. Moreover, the rising number of pre-screening diagnosis centers for detecting cancer, using liquid biopsy is expected to provide new market opportunities for the cancer biologics market in the North-America region. As per the Congressional Budget Office report, in 2019, the pharmaceutical industry spent $83 billion on research & development. 

Market Players Outlook

The major companies serving the global cancer biologics market are, Abbvie Inc., Amgen USA Inc., Bristol Myers Squibb Co., F.Hoffmann-La Roche Ltd., Glaxo Smith Kelvin., Atra Zeneca, Cue Biopharma., Eli Lilly and Co., Genmab A/S, Boehringer Ingelheim Pharmaceutical Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, Boehringer Ingelheim has acquired Abexxa Biologics, to adopt a new approach in the immunology and oncology area, to create advanced precision medicines for cancer. Furthermore, the company intends to launch new cancer immunotherapies for cancer patients, using Abexxa’s technology antibody-based drugs. ?

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cancer biologics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.